A protocol for 'enhanced pepsin digestion': A step by step method for obtaining pure antibody fragments in high yield from serum

Journal of Immunological Methods

Volumn 275, Issue 1-2, 2003, Pages 239-250

  Jones, R G A ^a   Landon, J ^b  

^a NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^b Newcastle Emlyn   (United Kingdom)

Author keywords

Aggregation; Antisera; Antitoxin; Antivenom; Pepsin; Sheep

Indexed keywords

ANTIBODY; PEPSIN A; VENOM;

ACIDITY; ANTIBODY PRODUCTION; ARTICLE; CLINICAL PROTOCOL; DIAFILTRATION; DIGESTION; MOLECULAR WEIGHT; NONHUMAN; PH; PRIORITY JOURNAL; SERUM; SOLUBILITY;

OVIS; OVIS ARIES;

EID: 0037376769     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-1759(03)00005-X     Document Type: Article

References (47)

1. Allen G. The affinity binding of digoxin to ovine anti-digoxin Fab (Digibind TM) preparations. Biologicals. 24:1996;19.
2. Baur X., Chen Z., Rozynek P., Duser M., Raulf-Heimsoth M. Cross-reacting IgE antibodies recognizing latex allergens, including Hev b 1, as well as papain. Allergy. 50:1995;604.
3. Benanchi P.L., Gazzei G., Giannozzi A. Purification of specific heterologous F(ab)2 fragments with DEAE-Zeta-Prep cartridges for ion-exchange chromatography. J. Chromatogr. A. 450:1988;133.
4. Bleeker W.K., Agterberg J., Rigter G., de Vries-van Rossen A., Bakker J.C. An animal model for the detection of hypotensive side effects of immunoglobulin preparations. Vox Sang. 52:1987;281.
5. Bleeker W.K., Agterberg J., Rigter G., Van Rooijen N., Bakker J.C. Key role of macrophages in hypotensive side effects of immunoglobulin preparations. Studies in an animal model. Clin. Exp. Immunol. 77:1989;338.
6. Bleeker W.K., Teeling J.L., Verhoeven A.J., Rigter G.M., Agterberg J., Tool A.T., Koenderman A.H., Kuijpers T.W., Hack C.E. Vasoactive side effects of intravenous immunoglobulin preparations in a rat model and their treatment with recombinant platelet-activating factor acetylhydrolase. Blood. 95:2000;1856.
7. Chippaux J.P., Lang J., Amadi-Eddine S., Fagot P., Le Mener V. Treatment of snake envenomations by a new polyvalent antivenom composed of highly purified F(ab)2: results of a clinical trial in northern Cameroon. Am. J. Trop. Med. Hyg. 61:1999;1017.
8. Davies M.E., Barrett A.J., Hembry R.M. Preparation of antibody fragments: conditions for proteolysis compared by SDS slab-gel electrophoresis and quantitation of antibody yield. J. Immunol. Methods. 21:1978;305.
9. Friesen A.D. Chromatographic methods of fractionation. Dev. Biol. Stand. 67:1987;3.
10. 2 antivenoms. An example: new polyvalent European viper antivenom (equine). Bon C., Goyffon M. Envenomings and Their Treatments. 1996;161 Foundation Marcel Merieux, Paris.
11. Haber E., Stone M. Extensive degradation of antibody by pepsin. Biochemistry. 6:1967;1974.
12. Harms A.J. The purification of antitoxic plasmas by enzyme treatment and heat denaturation. Biochem. J. 42:1948;390.
13. Hristova G. Application of DEAE-Sephadex A-50 for additional purification of antitoxic sera. Z. Immunitätsforsch. Allerg. Klin. Immunol. 135:1968;439.
14. Hristova G. Application of DEAE-Sephadex A-50 for additional purification of antitoxic sera. Prog. Immunobiol. Stand. 4:1970;99.
15. Hu J., Yokoyama T., Kitagawa T. Studies on the optimal immunization schedule of experimental animals: V. The effects of the route of injection, the content of Mycobacteria in Freund's adjuvant and the emulsifying antigen. Chem. Pharm. Bull. 38:1990;1961.
16. Imray, O., 1902. A process for removing albumin from bacterial and animal antitoxines and toxines. Br. Patent No. 18,340, 1.
17. Jones, R.G.A., 2001. Two North American arthropods of clinical significance: their venoms and the development of specific antivenoms. PhD Thesis, Faculty of Medicine, University of London, UK.
18. 2 fragments in high yield from serum. J. Immunol. Methods. 263:2002;57.
19. Jones R.G.A., Corteling R.L., To H.P., Bhogal G., Landon J. A novel Fab-based antivenom for the treatment of mass bee attacks. Am. J. Trop. Med. Hyg. 61:1999;361.
20. Jonsson M. Isoelectric spectra of native and base denatured crystallized swine pepsin. Acta Chem. Scand. 26:1972;3435.
21. Karlson-Stiber C., Persson H. Antivenom treatment in Vipera berus envenoming-report of 30 cases. J. Intern. Med. 235:1994;57.
22. Karlson-Stiber C., Persson H., Heath A., Smith D., al-Abdulla I.H., Sjostrom L. First clinical experiences with specific sheep Fab fragments in snake bite. Report of a multicentre study of Vipera berus envenoming. J. Intern. Med. 241:1997;53.
23. Kirkpatrick C.H. Allergic histories and reactions of patients treated with digoxin immune Fab (ovine) antibody. The Digibind Study Advisory Panel. Am. J. Emerg. Med. 9:1991;7.
24. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 227:1970;680.
25. Levine H.L., Ransohoff T.C., Kawahata R.T., McGregor W.C. The use of surface tension measurements in the design of antibody-based product formulations. J. Parenter. Sci. Technol. 45:1991;160.
26. Malasit P., Warrell D.A., Chanthavanich P., Viravan C., Mongkolsapaya J., Singhthong B., Supich C. Prediction, prevention, and mechanism of early (anaphylactic) antivenom reactions in victims of snake bites. Br. Med. J. 292:1986;17.
27. Meyer W.P., Habib A.G., Onayade A.A., Yakubu A., Smith D.C., Nasidi A., Daudu I.J., Warrell D.A., Theakston R.D.G. First clinical experiences with a new ovine Fab Echis ocellatus snake bite antivenom in Nigeria: randomized comparative trial with Institute Pasteur Serum (Ipser) Africa antivenom. Am. J. Trop. Med. Hyg. 56:1997;291.
28. Moran N.F., Newman W.J., Theakston R.D.G., Warrell D.A., Wilkinson D. High incidence of early anaphylactoid reaction to SAIMR polyvalent snake antivenom. Trans. R. Soc. Trop. Med. Hyg. 92:1998;69.
29. Nisonoff A., Wissler F.C., Lipman L.N., Woernley D.L. Separation of univalent fragments from the bivalent rabbit antibody molecule by reduction of disulfide bonds. Arch. Biochem. Biophys. 89:1960;230.
30. Osterberg T., Fatouros A., Neidhardt E., Warne N., Mikaelsson M. B-Domain deleted recombinant factor VIII formulation and stability. Semin. Hematol. 38(2 Suppl 4):2001;40.
31. Parfentjev, I.A., 1936. Method for purification of anti-toxins and the like. US Patent No. 2,065,196, 1.
32. Parfentjev, I.A., 1938. Treatment of anti-toxins and the like. US Patent No. 2,123,198, 1.
33. Pope C.G. The action of proteolytic enzymes on the antitoxins and proteins in immune sera: I. True digestion of the proteins. Br. J. Exp. Pathol. 20:1939;132.
34. Pope C.G. The action of proteolytic enzymes on the antitoxins and proteins in immune sera: II. Heat denaturation after partial enzyme action. Br. J. Exp. Pathol. 20:1939;201.
35. Porter R.R. The isolation and properties of a fragment of bovine-serum albumin which retains the ability to combine with rabbit antiserum. Biochem. J. 66:1957;677.
36. Porter R.R. The hydrolysis of rabbit gamma-globulin and antibodies with crystalline papain. Biochem. J. 73:1959;119.
37. Quarre J.P., Lecomte J., Lauwers D., Gilbert P., Thiriaux J. Allergy to latex and papain. J. Allergy Clin. Immunol. 95:1995;922.
38. Ryle A.P., Porter R.R. Parapepsins: two proteolytic enzymes associated with porcine pepsin. Biochem. J. 73:1959;75.
39. Saetang T., Treamwattana N., Suttijitpaisal P., Ratanabanangkoon K. Quantitative comparison on the refinement of horse antivenom by salt fractionation and ion-exchange chromatography. J. Chromatogr., B, Biomed. Sci. Appl. 700:1997;233.
40. Schultze H.E., Haupt H., Heide K., Heimburger N., Schwick H.G. Comparative investigations of purified diphtheria and tetanus T-components and their fragments. Immunochemistry. 2:1965;273.
41. Smith W.D., Dawson A.M., Wells P.W., Burrells C. Immunoglobulin concentrations in ovine body fluids. Res. Vet. Sci. 19:1975;189.
42. Smith D.C., Reddi K.R., Laing G., Theakston R.D.G., Landon J. An affinity purified ovine antivenom for the treatment of Vipera berus envenoming. Toxicon. 30:1992;865.
43. Stanworth D.R., Turner M.W. Immunochemical analysis of immunoglobulins and their sub-units. Weir D.M. Handbook of Experimental Immunology. 1978;6.1 Blackwell, Oxford.
44. Sutherland S.K. Serum reactions. An analysis of commercial antivenoms and the possible role of anticomplementary activity in de-novo reactions to antivenoms and antitoxins. Med. J. Aust. 1:1977;613.
45. Theakston R.D.G., Warrell D.A. Crisis in snake antivenom supply for Africa. Lancet. 356:2000;2104.
46. Waldesbuhl M., Allan R., Meylan A., Isliker H. Anticomplementary activity of gamma G-immunoglobulins and of their subunits. Immunochemistry. 7:1970;185.
47. Wilde H., Thipkong P., Sitprija V., Chaiyabutr N. Heterologous antisera and antivenins are essential biologicals: perspectives on a worldwide crisis [published erratum appears in Ann. Intern. Med. 1997, 126, 494]. Ann. Intern. Med. 125:1996;233.